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Two points stand out as being of par-
ticular interest: (1) Nck binding and 
PI3K binding appear to depend on dis-
tinct tyrosine motifs, though binding of 
both appears to be dependent on Fyn. 
(2) Nephrin-mediated PI3K activation 
leads to a loss of stress ﬁbers, whereas 
another slit diaphragm-associated pro-
tein, synaptopodin, has been reported 
to enhance stress ﬁber formation.12
Several interesting questions will 
now need to be addressed: What are 
the in vivo stimuli that lead to nephrin 
phosphorylation? Are Nck and PI3K 
recruited to and activated by nephrin 
independently, simultaneously? Once 
activated, are the signaling pathways 
they activate complementary, synergis-
tic, or antagonistic? Do synaptopodin 
and PI3K play antagonistic roles at the 
slit diaphragm? Perhaps most impor-
tantly, what role do these diﬀerent path-
ways play in vivo in the creation of foot 
processes during development and dur-
ing foot process eﬀacement and recovery 
in adult life? Although much remains to 
be discovered, it appears clear that the 
web connecting the slit diaphragm and 
the actin cytoskeleton will continue to 
grow in complexity and in importance 
for proteinuric kidney disease.
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Animal models of renal disease
K Susztak1, M Bitzer1, TW Meyer2 and TH Hostetter1
Mice have become a favored species to model disease. Many mouse 
strains have proven relatively resistant to some manipulations that 
have generated renal disease in other species. Kirchhoff et al. describe 
a means of producing hypertension, proteinuria, and glomerular 
sclerosis in a mouse strain.
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Clinical work is not enough. The all-important 
thing is to start the derivation of first approxi-
mation answers to clinical questions through 
experimental work on animals.
 -Thomas Addis1
Animal models have been an essential 
component of medical research for cen-
turies. Fulfilling Koch’s postulates usu-
ally requires an animal model as one 
step. Many mechanistic questions can be 
answered only through invasive proce-
dures or extreme exposures possible only 
in animals. Development of therapies 
and detection of toxicities almost always 
involve animal testing. To be sure, models 
can sometimes be uninformative or even 
misleading. Rats resist diphtheria toxin, 
but guinea pigs (and humans) succumb 
to it. Attempts to induce lung cancer with 
cigarette smoke in animals failed. Fleming’s 
initial studies of penicillin in rabbits may 
have retarded its trial in humans, as it was 
rapidly cleared in the animal.
Mice have become a favored species for 
study because their gene expression can 
be altered with relative ease. Indeed, this 
year’s Nobel Prize in Physiology or Medi-
cine went to three scientists instrumental 
in making gene targeting possible. Models 
that test the alteration of a gene suspected 
of having a key role have in some cases sup-
ported that suspicion.2 In other cases, the 
lack of phenotype in a knockout mouse 
may be perplexing.3 Overexpression has 
also been useful in testing a pathway of 
injury, for example, transforming growth 
factor-β.4 For medical researchers, the 
weights of both the positive and the nega-
tive results depend, of course, on whether 
the gene of interest functions and is regu-
lated similarly in mice and humans. This 
may not always be the case.5
Mouse models using single gene knock-
out or overexpression have in many cases 
produced palpable renal disease and 
have in some cases produced diseases 
very faithful to the human condition. 
However, mice have generally not been 
tractable for producing more complex 
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disease. Moreover, they seem to yield far 
less ﬂorid pathology compared with the 
same models in rats. For example, the 
remnant kidney model, when produced 
in rats, leads to hypertension, glomeru-
lar sclerosis, interstitial ﬁbrosis, protein-
uria, and eventually uremic death. When 
high-grade nephrectomy was applied to 
mice, little or no injury occurred.6 Simi-
larly hypertensive renal disease is easily 
engendered in rats by several maneuvers, 
and substantial kidney injury can ensue. 
Hypertension and related renal damage 
has been diﬃcult to induce in mice.7
The paper by Kirchhoﬀ and colleagues8 
(this issue) presents a convincing model for 
hypertension-induced injury in the mouse. 
The investigators used the C57BL/6N 
mouse, which has seemed the most resist-
ant to induction of renal injury of all the 
common mouse strains. In keeping with 
the general observation that mice are more 
resistant than rats to the usual manipula-
tions, the model required the combination 
of unilateral nephrectomy, saline for drink-
ing water, and mineralocorticoid admin-
istration plus angiotensin II infusion to 
generate hypertension and injury. More 
extreme results usually appear in the rat 
without the need for angiotensin II infu-
sion. Nevertheless, substantial pathology 
resulted with proteinuria, glomerular scle-
rosis, cardiac hypertrophy, and ﬁbrosis.
Models of complex disease are most 
useful for dissecting mechanistic path-
ways and for testing therapies. Unraveling 
pathways of diseases such as hypertensive 
nephrosclerosis or diabetic nephropathy 
should be facilitated by having a strong 
model, particularly one in which puta-
tive eﬀectors could be selectively altered 
by genetic engineering. If the model 
has high ﬁdelity to the human disease, 
one expects that not only will common 
mechanisms exist but the model will be 
a fertile one for testing therapy.
A potential limitation of induced 
models is inherent in the means of 
inducing them. For example, the model 
of Kirchhoff et al. clearly proceeds 
initially from the actions of the renin–
angiotensin–aldosterone system.8 We 
could presumably show that agents that 
block that system limit injury in this 
model. Such results would not be help-
ful. The model could, however, help us 
identify the participation of more distal 
elements in the pathway of injury down-
stream from the inciting factor, for exam-
ple, plasminogen activator inhibitor and 
monocyte chemoattractant protein in 
the Kirchhoﬀ et al. model. The ﬁnding 
of common distal pathways of injury in 
various animal models would spur eﬀorts 
to determine whether blocking these 
pathways limits renal injury in humans.
Mimicking the histopathology of a 
human disease, although attractive, may 
not always be crucial. Rat models of dia-
betic nephropathy oﬀer this lesson. The 
usual chemically induced model of dia-
betes uses the β-cell toxin streptozotocin. 
With time after streptozotocin in the 
rat, proteinuria develops and sclerotic 
glomeruli eventually appear. However, 
Kimmelstiel-Wilson nodular lesions or 
even clear mesangial expansion never 
develop. Falls in glomerular filtration 
rate have not been regularly reported. 
Arterial hypertension does not occur. 
Perhaps the lack of some of these features 
in the model reﬂects the fact that human 
diabetic nephropathy takes at minimum 
ﬁve years to be clinically notable after the 
onset of diabetes, and rats live only two 
years. This problem may be compounded 
as investigators rarely follow the rat mod-
els for even one year. Whether chronic 
disease progression scales with the known 
interspecies diﬀerences in metabolism and 
lifespan is unknown.9 Nevertheless, the 
renal lesions of this streptozotocin model 
in the rat responded to glycemic control 
and forecast the eﬃcacy of angiotensin-
converting enzyme inhibition. Eﬀorts to 
develop a mouse model of diabetic neph-
ropathy have yielded useful results.10 
They have largely focused on merging 
targeted gene manipulations with genetic 
or streptozotocin models of diabetes. 
However, like the rat model, the mouse 
ones remain imperfect, at least as judged 
by human pathology. Maybe imperfection 
is not always so bad.
Even though the ﬁnal test for animal 
models is their usefulness in understand-
ing and treating human disease, the dif-
ferences in renal vulnerability among 
humans, mice, and rats are intriguing 
and, if understood, could inform the 
clinical problem. In principle, comparing 
susceptibility between inbred strains of 
mice might allow for crossbreeding and 
identiﬁcation of susceptibility genes. This 
approach is hard, not least because of the 
time required to document chronic renal 
injury, but has been successful with rela-
tively rapidly developing injury, as in the 
case of the discovery of a genetic locus 
conferring predisposition to doxorubicin 
nephrosis.11 The similarities and diﬀer-
ences in gene expression in the major 
nephronal segments in the three species 
might also provide insights. Finally, most 
of the attempts at modeling renal disease 
in mice have used inbred strains, whereas 
humans and most of the commonly used 
rat strains are outbred. Thus, a wider 
array of potential susceptibility genes in 
the outbred state might yield more vari-
able phenotypes including one closer to 
human disease. 
Animal models can mislead but can 
instruct even when ﬂawed, but they are 
too often regarded as ends in themselves. 
Instead, they must be repeatedly com-
pared with the clinical condition and 
measured only by their applicability to 
mechanistic understanding and thus dis-
covery of therapy. Ideally, an iterative back 
and forth between cage and clinic would 
propel medical investigation. It seems to 
us that the pharmaceutical industry often 
pursues such interaction with a vigor not 
seen in academia. Diﬀerences in resources 
may be only a part of that apparent diﬀer-
ence. Rather, distinctions between basic 
and clinical research often prove stronger 
than the focus on the disease.
The early renal investigator Thomas 
Addis, who famously championed a 
team approach to research, embodied the 
productive tension between animal and 
human studies. He perhaps carried this 
strategy to the extreme by using a corner 
of his laboratory to see the patients with 
Bright’s disease whom he studied and 
treated.1,12 His large vivarium was close 
at hand. In 1946 he wrote, “for the last 
few years we have not asked any ques-
tions from our rats that did not give us 
at least a hope of getting answers that 
referred to our patients.”1 We suspect 
that Addis would be fascinated by our 
modern models of renal disease but 
would want to know how we planned to 
use them to understand human disease 
and treat our patients.
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Low-molecular weight iron 
dextran and iron sucrose have 
similar comparative safety 
profiles in chronic kidney disease
M Auerbach1 and K Al Talib2
Serious adverse events that occur with the administration of iron 
dextran are due to the high molecular weight preparations.  Conclusions 
that iron sucrose and ferric gluconate are safer than iron dextran may be 
premature.  Published literature comparing safety profiles of available 
parenteral iron products is reviewed.  Administration of iron salts to 
pre-dialysis patients with chronic kidney disease may not be optimal.  
We recommend the total dose infusion of low molecular weight iron 
dextran as an option for iron replacement.
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Theoretical concerns about the long-
term toxicity of intravenous iron in 
renal disease have not been supported 
by recent observational studies of dialy-
sis patients.1,2 Publications also continue 
to raise concerns over anaphylaxis with 
iron dextran and infusion-related adverse 
events. Recent publications in Kidney 
International3,4 raise questions about the 
optimal method of administering intra-
venous iron. They propose an aggressive 
repletion regimen of iron sucrose given 
as a 500 mg infusion over 3 hours. Their 
recommendations are based on two 
premises: ﬁrst, that iron dextran is less 
safe than iron sucrose (Venofer; Ameri-
can Regent, USA, and Vifor, Switzerland) 
and, second, that the higher-than-rec-
ommended dosing of iron sucrose5 is 
justified by a considerably increased 
convenience to patient and physician. 
However, it is important to point out 
that the authors do not directly compare 
the safety of the two agents. Furthermore, 
there is no mention of the relevant dif-
ferences between the low-molecular 
weight iron dextran, INFeD (Watson, 
USA) and CosmoFer (Pharmacosmos, 
Denmark), and high-molecular weight 
preparations of iron dextran, Imferon 
(Fisons, UK) and Dexferrum (American 
Regent, USA, and Vifor, Switzerland). 
The published safety diﬀerences among 
these preparations will be discussed later 
in this Commentary.
One should not consider optimal a 
regimen of intravenous iron sucrose 
given as 500 mg over 3 hours for 2 con-
secutive days, as higher doses of intra-
venous iron are best given as a single 
total-dose infusion of low-molecular 
weight iron dextran.6 This method of 
intravenous iron administration is more 
convenient to physician and patient, is 
less expensive, allows the administra-
tion of doses up to 3,000 mg in a single 
setting, and is not more toxic. Both iron 
sucrose and ferric gluconate can be given 
as 5-minute infusions of 200–300 mg, but 
larger doses, even if given over a longer 
interval, are associated with high inci-
dences of minor, irritating, uncomfort-
able vasoactive reactions and have been 
proscribed.5 Chandler et al. reported on 
249 patients who received 335 iron infu-
sions of iron sucrose at doses of 200–500 
mg, all administered over 2 hours.5 The 
authors concluded that adverse events 
with the 400 and 500 mg doses were too 
high to allow recommendation of rou-
tine use of these dosage regimens over 
2 hours. The description of 5%–12% 
of patients who experienced infusion-
related side eﬀects during the study3,4 
represents a ﬁve- to tenfold increase in 
such reactions compared with those seen 
with low-molecular weight iron dextran 
or lower doses of iron sucrose.
Numerous publications now document 
that anaphylaxis, the serious adverse 
event associated with iron dextran, is 
largely due to the two high-molecular 
weight products, Imferon, which is no 
longer available, and Dexferrum, which 
is not recommended.7–15 Characteristics 
of the four available iron preparations 
